Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Validation of a Clinical Screening Grid for Syndromic Schizophrenia [NA]
A ClinicalTrials.gov update shows termination of a trial validating a screening grid for syndromic schizophrenia.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training. [Phase 2]
Phase 2 clinical trial evaluating the effectiveness and efficacy of combining Integrated Psychological Therapy with Metacognitive Training f…
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: The Effect of Logotherapy-Based Psychoeducation Applied to Family Members of Individuals Diagnosed with Schizophrenia on Finding Meaning, Hope and Depression [NA]
The study investigates logotherapy-based psychoeducation for family members of individuals with schizophrenia to impact meaning, hope, and d…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) [Phase 1]
Phase 1 study of MK-5720 in participants with schizophrenia completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Safety and Tolerability of Open-Labeled Iloperidone in Adolescents [Phase 4]
This Phase 4 open-label study evaluates the safety and tolerability of iloperidone in adolescents with schizophrenia or bipolar I disorder a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Contingency Management for Problematic Behavior Reduction in the Community [NA]
A completed clinical trial evaluating contingency management to reduce problematic behaviors in community settings among individuals with sc…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Neurocognition After Perturbed Sleep [NA]
This is a completed clinical trial assessing neurocognition after perturbed sleep in individuals with schizophrenia.
-
FDA approval · 2025-02-28FDA Approved: LYBALVI — Supplemental Application (Alkermes, Inc.)
FDA approved a supplemental application for LYBALVI (olanzapine and samidorphan) expanding its labeling to include use for schizophrenia and…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia [Phase 4]
Phase 4 clinical trial update evaluating high-dose lurasidone for treatment-resistant schizophrenia.
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial. [NA]
This document provides an update on a multicenter stepped-wedge randomized trial to assess the efficiency of BREFORM in schizophrenia, with …
-
FDA approval · 2025-02-26FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for Fluphenazine Decanoate from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2025-02-26FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for Fluphenazine hydrochloride submitted by Novadoz Pharmaceuticals LLC. The approval pertains to a …
-
EMA approval · 2025-02-26EMA Authorised: Aripiprazole Accord (aripiprazole) — Accord Healthcare S.L.U.
The EMA authorised Aripiprazole Accord as a generic aripiprazole product for schizophrenia and bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: The Efficacy of Neural Stimulation in Individuals With Schizophrenia [NA]
This update reports the completed results of a neural stimulation intervention in individuals with schizophrenia. Results were posted on 202…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders [NA]
A clinical trial update noting ongoing recruitment for YoGI, a yoga-based group intervention for in-patients with schizophrenia spectrum and…
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial [NA]
A randomized placebo-controlled trial is evaluating whether melatonin can improve schizophrenic symptoms in patients with schizophrenia or r…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Uppsala Psychosis Cohort
The Uppsala Psychosis Cohort clinical trial is currently recruiting, sponsored by Uppsala University, investigating schizophrenia and psycho…
-
FDA approval · 2025-02-19FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Fluphenazine Decanoate by Hikma Pharmaceuticals USA Inc. for continued marketing of this long-ac…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia [Phase 2]
Phase 2 clinical trial update examining a combination of NMDA-enhancing and antioxidant treatments for schizophrenia; recruitment is current…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia [Phase 2]
A Phase 2 clinical trial in China is recruiting to evaluate an NMDA-enhancing treatment for cognitive dysfunction in schizophrenia.
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating a combination of NMDA-enhancing and anti-inflammatory treatments for schizophrenia; currently recruiting.
-
FDA approval · 2025-02-18FDA Approved: ARIPIPRAZOLE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application from Bionpharma Inc. for aripiprazole (generic), enabling its continued commercialization with the a…
-
FDA approval · 2025-02-14FDA Approved: ARIPIPRAZOLE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for aripiprazole from Bionpharma Inc., enabling the generic product to be marketed in the United Sta…
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography [NA]
A clinical trial is recruiting to evaluate personalized magnetoencephalography-guided repetitive transcranial magnetic stimulation (RTMS) fo…
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Relationship Between Physical Fitness and Psychopathology, Cognition and Quality of Life in Patients Diagnosed With Schizophrenia: a Mixed Method Study.
This ClinicalTrials.gov entry describes a mixed-method study examining how physical fitness relates to psychopathology, cognition, and quali…